share_log

康沣生物-B(06922)发布中期业绩 股东应占亏损5217.1万元 同比扩大202.2%

Kangfeng Biotechnology-B (06922) released its interim results, with a shareholder's net loss of 52.171 million yuan, a year-on-year increase of 202.2%.

Zhitong Finance ·  Aug 28 18:42

Tongcai Financial APP reported that Kangfeng Biotech-B (06922) released its performance for the six months ending June 30, 2024. The group achieved revenue...

Tongcai Financial APP reported that Kangfeng Biotech-B (06922) released its performance for the six months ending June 30, 2024. The group achieved revenue of 19.475 million yuan (RMB), an increase of 2.97% compared to the same period last year. The loss attributable to the owners of the parent company expanded by 202.2% to 52.171 million yuan, with a basic loss per share of 0.22 yuan.

The announcement stated that the revenue increased by 3.0%, mainly due to the increase in sales of the group's pulmonary nodule localization needles.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment